PRESS RELEASES

Occam Expands European Practice with CFO Placement

In early 2025, Occam Global placed McDavid Stilwell as CFO of CPTx, a company pioneering the development of in vivo genetic medicines built on single-stranded DNA. CPTx’s lead development programs include a next-generation in vivo CAR-T therapy and a novel, programmable, non-viral self-delivering gene nanocarrier.

Stilwell is an industry veteran with more than 25 years of experience in finance, corporate development, investor relations, and communications. Previously, he served as CFO at Coherus Biosciences as the company launched multiple new products into the US market. Earlier in his career, he held leadership roles at Sangamo Therapeutics, a pioneer in gene editing, and several other biotech companies.

Stilwell received a BA from St. John’s College and an MBA from Harvard Business School.